Hims & Hers Health Inc.
(NYSE:HIMS) is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them.
Hims & Hers Health stock is building positive momentum.
What's pushing HIMS stock higher?
FDA Panel Splits, Recommends Peptides for 503A List The FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend that BPC-157, KPV and TB-500 each be added to the 503A Bulks List.
